Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Vicor Corporation Common Stock (VICR) Price & Performance

Cassava Sciences IncTrade
Vicor Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Vicor Corporation Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while Vicor Corporation Common Stock trades at $234.03 (market cap $12.30B). The key difference: Vicor Corporation Common Stock is far larger — about 342.5× Cassava Sciences Inc's market cap, and Vicor Corporation Common Stock is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Vicor Corporation Common Stock for 0 Days on average.

FLNAVICR
Market Cap
$35.91M$12.30B
Volume
323,2461,052,269
Sector
HealthTechnology
52-Week High
$4.64$379.78
52-Week Low
$0.68$57.31
Typical Hold Time
38 Days0 Days
Enterprise Value
-$46.77M$11.86B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.

The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.

Vicor Corporation Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
52% Buy48% Sell
Avg holding period · 38 Days
VICR
100% Buy0% Sell
Avg holding period · 0 Days

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About Vicor Corporation Common Stock

Vicor Corporation designs, manufactures, and markets modular power components and complete power systems, serving high-performance computing, data center, industrial, automotive, and aerospace and defense markets.

Read more on VICR →